Toggle Health Problems and D

Good Vitamin D receptor reduced bladder cancer and cisplatin deaths – April 2019

Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk

Cancer Medicine: 10 April 2019 https://doi.org/10.1002/cam4.2119
Brittany L. Bunch Yingyu Ma Kristopher Attwood Lauren Amable Wei Luo Carl Morrison Khurshid A. Guru Anna Woloszynska‐Read … See all authors


derived from Grassroots 2013
Items in both categories Cancer - Bladder and Vitamin D Receptor are listed here:

Chemotherapy and Cisplatin

Items in both categories Vitamin D Receptor and  Cancer

Vitamin D Receptor had the following - April 2019

4.6Breast Cancer 16.9 X another study
3.1 Colon Cancer survival
2.7Gastric Cancer
2.4Lung Cancer
1.6Prostate Cancer while black

Vitamin D Receptor table shows what compensates for low VDR activation
Compensate for poor VDR by increasing one or more:

1) Vitamin D supplement  Sun
Ultraviolet -B
Vitamin D in the blood
and thus in the cells
2) MagnesiumVitamin D in the blood
 AND in the cells
3) Omega-3 Vitamin D in the cells
4) Resveratrol Vitamin D Receptor
5) Intense exercise Vitamin D Receptor
6) Get prescription for VDR activator
   paricalcitol, maxacalcitol?
Vitamin D Receptor
7) Quercetin (flavonoid) Vitamin D Receptor
8) Zinc is in the VDRVitamin D Receptor
9) BoronVitamin D Receptor ?,
10) Essential oils e.g. ginger, curcuminVitamin D Receptor
11) ProgesteroneVitamin D Receptor
12) Infrequent high concentration Vitamin D
Increases the concentration gradient
Vitamin D Receptor
13) Sulfroaphane and perhaps sulfurVitamin D Receptor
14)Butyrate especially gutVitamin D Receptor

Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above

 Download the PDF from VitaminDWiki



Suspect that >20ng Vitamin D PLUS Good Vitamin D receptor would be even better

Vitamin D3 (VitD) deficiency is linked to increased incidence and worse survival in bladder cancer (BCa). In addition to cystectomy, patients are treated with cisplatin‐based chemotherapy, however 30%‐50% of patients do not benefit from this treatment. The effects of VitD deficiency on response to chemotherapy remain unknown.

To test effects of VitD supplementation on the response to cisplatin we analyzed patient serum VitD levels and correlated that with survival. In vivo, VitD deficient mice were treated with cisplatin, with or without pretreatment with the active VitD metabolite, 1,25 dihydroxyvitamin D3 (1,25D3). Lastly, using BCa cell lines, T24 and RT‐112, the mechanism of action of 1,25D3 and cisplatin combination treatment was determined by apoptosis assays, as well as western blot and RT‐PCR.

In this study, we determined that low serum 25 hydroxyvitamin D3 (25D3) levels was significantly associated with worse response to cisplatin. Pretreating deficient mice with 1,25D3, reduced tumor volume compared to cisplatin monotherapy. In vitro, 1,25D3 pretreatment increased the apoptotic response to cisplatin. 1,25D3 pretreatment increased expression of TAp73 and its pro‐apoptotic targets, in a VDR dependent manner. VDR and its transcriptional targets were induced after 1,25D3 treatment and further increased after the combination of 1,25D3 and cisplatin in a TAp73 dependent manner.

Conclusions: Our data suggest that VitD deficiency could be a biomarker for poor response to cisplatin, and pretreating with VitD can increase the apoptotic response to cisplatin through VDR and TAp73 signaling crosstalk.

Created by admin. Last Modification: Thursday April 11, 2019 17:10:25 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
11749 Bladder cancer survival.jpg admin 11 Apr, 2019 23.45 Kb 658
11748 VDR Cancer.jpg admin 11 Apr, 2019 23.33 Kb 704
11747 cisplatin in bladder cancer.pdf admin 11 Apr, 2019 1,004.29 Kb 608